# Pascal Soriot

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/pascal-soriot
Canonical HTML page: https://getbiobrief.com/entity/pascal-soriot

## Recent coverage (3 stories)

### AstraZeneca and BMS in Talks for £300bn Biotech Consolidation Play
2026-08-03 09:56:53 · Sentiment: Neutral · Impact: 9/10 · Sources: 4

The potential merger could dramatically reshape oncology and cardiovascular R&D pipelines, triggering a wave of consolidation among biotech firms seeking scale to compete with the new behemoth.
Full story: https://getbiobrief.com/story/astrazeneca-bms-biotech-merger-300bn

### AstraZeneca, BMS Eye $400B Union to Build Cancer Powerhouse
2026-08-02 23:37:29 · Sentiment: Neutral · Impact: 9/10 · Sources: 2

The merger would unite two cancer powerhouses, combining blockbusters like Opdivo and Tagrisso into a pipeline with more than 100 clinical programs. Biotech investors see a fusion of immuno-oncology and targeted therapy leadership.
Full story: https://getbiobrief.com/story/astrazeneca-bms-oncology-pipeline-merger

### AstraZeneca CEO Pascal Soriot Receives £17.7M Pay Package for 2025
2026-02-24 20:14:28 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

AstraZeneca CEO Pascal Soriot's total compensation for 2025 reached £17.7 million, driven by significant performance-linked bonuses. The payout reinforces Soriot's position as one of the highest-paid executives in the FTSE 100 as the company pursues an ambitious $80 billion revenue target by 2030.
Full story: https://getbiobrief.com/story/astrazeneca-pascal-soriot-pay-2025

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.